• Advances in pediatric surgery
• /
• 제3권2호
• /
• pp.143-147
• /
• 1997

Bacillus Calmette-Guerin(BCG) lymphadenitis is a complication of post-BCG vaccination and its treatment is still controversial. Eighty patients who had been operated for BCG lymphadenitis from 1987 to 1996 were reviewed. Thirty-one of them were treated with antituberculous drugs(mean duration: 3 months) preoperatively and 49 patients were not given preoperative antituberculous medication. No one was treated with antituberculous drugs postoperatively. Operation methods were excision(72) and partial excision with curettage(8). There was no statistical difference in recurrence rate between groups In two patients(2.5 %) treated with preoperative antituberculous drugs, the lesions recurred after operation. The results suggest that preoperative antituberculous medication does not play any role in the treatment of BCG lymphadenitis and in preventing recurrence in surgically excised cases.

• Applied Microscopy
• /
• 제40권4호
• /
• pp.193-200
• /
• 2010

이 실험은 Ehrlich 종양세포를 샅부위에 이식한 후 고농도의 BCG(Bacillus Calmette-Guerin)를 피부밑조직에 반복 투여하였을 때, 샘창자점막의 형태학적 변화와 함께 DNA합성지수를 비교 연구하고자 3H-thymidine을 투여한 후 자기방사법적 연구를 시행하였다. 실험동물로는 체중 25 g 내외의 ICR 흰생쥐를 사용하였으며 정상대조군을 제외한 종양대조군과 BCG투여군의 동물에는 샅부위 피부밑조직에 각각 $1{\times}10^7$의 Ehrlich 종양세포를 이식하였다. BCG투여군은 종양세포이식 다음날부터 농축 건조된 BCG를 생리식염수에 용해시킨 다음, 일정량을 하루건너 한 번씩 7회 피부밑조직에 주사하였다. 종양대조군은 종양세포이식 후에 생리식염수를 하루건너 한 번씩 7회 피부밑조직에 주사하였고, 정상대조군은 종양세포를 이식하지 않은 동물을 사용하였으며 각 군에는 5마리씩의 동물을 배정하였다. 자기방사법적 관찰을 위하여는 약제를 마지막으로 주사한 다음날 3H-thymidine $0.7{\mu}Ci$/gm를 꼬리에 한차례 정맥주사하고, 70분 후 도살하여 샘창자조직을 떼어내어 10% 포르마린으로 고정하였다. 관찰은 샘창자조직이 세로로 잘 절단된 창자움 부위를 택하여 점막근육판을 따라 점막길이 3.5mm의 창자샘상피에 분포하는 3H-thymidine 표지세포의 수를 계수하였으며, 일반조직 관찰을 위해서는 hematoxylineosin (H-E)염색을 시행하였다. 일반조직관찰에서 종양대조군과 BCG투여군은 정상대조군에 비해 샘창자 점막 고유판에 림프구와 호산성백혈구가 다수 관찰된 것 이외에는 형태적으로 큰 변화를 볼 수 없었다. 자기방사법적 연구에서 정상대조군, 종양대조군 및 BCG투여군은 점막길이 3.5 mm 당 출현하는 표지세포수가 각각 632.3 (${\pm}14.47$), 761.7 (${\pm}27.65$) 및 505.0 (${\pm}17.09$)개였다. 이상의 결과를 종합해보면 Ehrlich 종양세포를 이식한 생쥐에 BCG를 반복 투여하면 샘창자 점막상피세포의 DNA합성을 유의하게 억제하면서도 형태적인 변화가 경미하였으므로 BCG는 항암치료시 항암효과를 높일 수 있는 좋은 약제라고 생각된다.

• Korean Journal of Radiology
• /
• 제1권2호
• /
• pp.114-117
• /
• 2000

Disseminated mycobacterial infection after bacillus Calmette-Guerin (BCG) vaccination is a very rare disorder, occurring mostly in patients with immunologic deficiency. We report a case of disseminated BCG infection in a 16-month-old girl with severe combined immunodeficiency. Plain radiographs showed multiple osteolytic lesions in the femora, tibiae, humerus, and phalanges. Abdominal sonography and CT scanning revealed multiple nodules in the spleen, and portocaval lymphadenopathy.

• Bulletin of the Korean Chemical Society
• /
• 제35권3호
• /
• pp.933-937
• /
• 2014

A derivative of Mycobacterium bovis Bacillus Calmette-Guerin (BCG) has been used for the preparation of tuberculosis vaccines. To establish a Korean tuberculosis vaccine derived from BCG-Pasteur $1173P_2$, genome sequencing of a BCG-Korea strain was completed by Joung and coworkers. A comparison analysis of the genome sequences of the BCG-Pasteur $1173P_2$ and BCG-Korea strains showed marginal increases in the total genome length (~0.05%) and the number of genes (~4%) in the BCG-Korea genome. However, how the genomic changes affect the BCG-Korea protein expression levels remains unknown. Here, we provide evidence of the proteomic alterations in the BCG-Korea strain by using a SWATH-based mass spectrometric approach (Sequential Window Acquisition of all THeoretical mass spectra). Twenty BCG proteins were selected by top-rank identification in the BCG proteome analysis and the proteins were quantified by the SWATH method. Thirteen of 20 proteins showing significant changes were enough to discriminate between the two BCG proteomes. The SWATH method is very straightforward and provides a promising approach owing to its strong reliability and reproducibility during the proteomic analysis.

• 대한미생물학회지
• /
• 제22권2호
• /
• pp.163-166
• /
• 1987

BCG 감염마우스의 비장으로부터 BCG 항원에 대한 수용체를 가진 세포를 BCG 항원으로 감작시킨 면양 적혈구(SRBC)를 이용한 rosette 방법으로 분리하였다. SRBC에 흡착되는 적정 BCG 항원 농도를 알아보기 위하여 tannic acid(1:20,000)으로 전처리한 SRBC에 여러 농도의 BCG 항원으로 작용시킨 결과 $50\;{\mu}g/ml$의 BCG 항원으로 반응시킨 경우 가장 높은 rosette 형성을 관찰할 수 있었다. 비장세포와 항원처리 SRBC와의 작용시간에 따른 rosette 형성율은 1시간 후에 최고에 달하였고 시간의 경과한다 하여 증가하지 않았다. BCG 감염후 1주에서 8주까지 비장에서의 rosette 형성세포를 관찰한 결과 감염 $3{\sim}4$주 후부터 가장 높은 rosette 형성율을 보였으며 이때 rosette 형성세포는 전 비장세포중 $5{\sim}7%$를 차지하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권6호
• /
• pp.2935-2941
• /
• 2012

Biological response modifiers (BRMs) can alter interactions between the immune system and cancer cells to boost, direct, or restore the body's ability to fight disease. Mice with ethylnitrosourea- (ENU) induced leukemia were here used to monitor the therapeutic efficacy of lipopolysaccaride (LPS), Bacillus Calmette Guerin (BCG) and sheep erythrocytes (SRBC). Flow cytometry based CD34+ positivity analysis, clonogenicity, proliferation and ultrastructure studies using scanning electron microscopy (SEM) of stem cells in ENU induced animals with and without BRMs treatment were performed. BRMs improved the stem-stromal relationship structurally and functionally and might have potential for use as an adjunct in human stem cell therapy.

• Toxicological Research
• /
• 제6권1호
• /
• pp.21-28
• /
• 1990

This study was undertaken to evaluate the immune responses to sheep red blood cell (SRBC) and potential anti-tumor effect of Bacillus Calmette-Guerin (BCG) in the mice bearing rumor induced by DMBA. The frequencies of tumor appearances were 62% in DMBA-treated mice and 14% in DMBA and BCG-treated group, respectively. Cellular immune response such as delayed-type hypersensitivity (DTH) to SRBCs, natural killer (NK) cell activity and antigen-binding cell (ABC) assay were decreased apparently in the tumor bearing mice compared to the normal controls. Humoral immune responses such as hemagglutinin (HA) and hemolysin (HE) were noted to be reduced in the tumor bearing mice, but the spleen index increased in tumor bearing mice. All the immunological parameters in the DMBA and BCG-group appeared to be higher than those of only DMBA-treated group. These results indicated that DMBA-induced tumor suppressed host immune responses. Also, they imply the idea that BCG enhanced the immune responses of tumor-bearing host and antitumor effects.

• 대한수의학회지
• /
• 제52권2호
• /
• pp.89-97
• /
• 2012

Mycobacterial cell-wall skeleton (CWS) is an immunoactive and biodegradable particulate adjuvant and has been tried to use for immunotherapy. The CWS of Mycobacterium bovis bacillus Calmette-Guerin (BCG-CWS) was studied as an universal vaccine vehicle for antigen conjugation, to develop potentially effective and safe vaccine. Although a variety of biological activities of BCG-CWS have been studied, the effects of BCG-CWS on spleen cells are not fully elucidated. Using MTT assay and trypan blue exclusion test, we found that BCG-CWS significantly enhanced the viability and proliferation of cells. Multiple clusters, indicating proliferation, were observed in BCG-CWS-treated spleen cells and surface marker staining assay revealed that BCG-CWS promoted the proliferation of $CD19^+$ B lymphocyte rather than $CD4^+$ or $CD8^+$ T lymphocyte. In addition, BCG-CWS up-regulated the expression of anti-apoptotic molecules such as bcl-2, bcl-xL. BCG-CWS increased the surface expression of CD25 and CD69 as well as IL-2 production of spleen cells, suggesting increased activation. Furthermore, BCG-CWS enhanced the antigen-specific cell proliferation and interferon-gamma production of spleen cells. Taken together, these results demonstrate the immunostimulatory effects of BCG-CWS on spleen cells via multiple mechanisms, providing valuable information to broaden the use of BCG-CWS in clinical and research settings.

• Applied Microscopy
• /
• 제35권3호
• /
• pp.153-163
• /
• 2005

이 연구는 생쥐의 샅부위에 Ehrlich 암세포를 이식한 후 BCG (Bacillus Calmette-Guerin)를 투여하였을 때, 위점막 으뜸세포의 미세구조에 미치는 영향을 알아보기 위하여 시행하였다. 실험동물로는 체중 25 g 내외의 ICR생쥐를 사용하였으며 정상대조군과 실험군으로 구분하였다. 정상대조군 이외의 실험군 동물들은 샅부위 피부밑조직에 각각 $1x10^7$개의 Ehrlich암세포를 이식한 후, 다음날부터 BCG 투여군은 BCG를 피부밑조직에 격일 간격으로 7회 투여했으며, 종양대조군은 암세포이식 후에 약제 대신 0.2 mL의 생리식염수를 피부밑조직에 격일간격으로 7회 주사하였고, 정상대조군은 암세포를 이식하지 않은 동물을 사용하였다. 모든 실험군은 마지막 주사한 다음날 오전 10시에서 11시 사이에 ether마취하에 앞배벽을 열어 위조직을 절취하였다. 절취한 조직은 통상적인 방법으로 전자현미경관찰을 위한 표본을 작성한 후, JEM 100 CX-II 전자현미경으로 비교 관찰하였다. 각 세포는 5,300 배율로 촬영한 후 3배로 확대 인화한 사진을 비교 관찰하였으며, 각 실험군마다 200개 이상의 과립의 지름과 사립체의 크기(장경)를 측정하였으며 student-t test를 이용하여 통계처리 하였다. BCG 투여군의 으뜸세포는 과립세포질세망과 골지복합체의 수조가 다소 팽대되고 수초구조가 다소 많이 관찰되는 이외는 정상대조군에 비해 큰 차이가 없었다. 으뜸 세포의 분비과립의 크기는 정상대조군, 종양대조군 및 BCG 투여군의 경우 각각 $0.98({\pm}0.108){\mu}m,\;1.05({\pm}0.092){\mu}m$ 및 $0.93({\pm}0.053){\mu}m$ 였다. 으뜸세포의 사립체의 크기는 정상대조군, 종양대조군 및 BCG 투여군이 각각 $0.80({\pm}0.130){\mu}m,\;0.83({\pm}0.143){\mu}m$ 및 $0.72({\pm}0.078){\mu}m$ 였다. 이상의 결과를 종합해보면 BCG를 반복 투여하면 위점막으뜸세포의 분비과립이 약간 작아지는 등 분비기능이 다소 억제되나 그 정도가 경미하여 으뜸세포의 분비기능에 큰 손상을 주지 않는 것으로 생각된다.

• Biomolecules & Therapeutics
• /
• 제12권3호
• /
• pp.133-137
• /
• 2004

Present review is built on base of research work on Ganoderma lucidum in our laboratory. A great deal of experimental evidence has suggested that the pharmacological activities of Ganoderma lucidum (Lingzhi) are related to anti-oxidative and free radical scavenging activity. The anti-oxidative and free radical scavenging effects of polysaccharides and triterpenoids isolated from Ganoderma lucidum in different oxidative injury models including tert-butylhydroperoxide (tBOOH)- damaged mice peritoneal macrophages, alloxan-induced diabetes, experimental liver injury models induced by carbon tetrachloride (CCl4), D-galactosamine (DGal) and Bacillus Calmette-Guerin (BCG) plus lipopolysaccharides (LPS) were investigated. It is also demonstrated that Lugu lingzhi, one of Ganoderma product, significantly inhibited LDL oxidation mediated by endothelial cells and decreased monocyte adhesion to endothelial cell (EC) induced by Oxidative low-density lipoprotein (ox-LDL) and advanced glycation endproducts (AGE). Lugulingzhi-treated serum could markedly inhibit the expression of intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-l) induced by ox-LDL and AGE.